Compare Natera Inc. Common Stock (NTRA) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs ABRDN Physical Gold Shares ETF — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while ABRDN Physical Gold Shares ETF trades at $39.57 (market cap $7.18B). The key difference: Natera Inc. Common Stock is far larger — about 7.9× ABRDN Physical Gold Shares ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| NTRA | SGOL | |
|---|---|---|
Market Cap | $57.03B | $7.18B |
Volume | 1,131,157 | 3,881,341 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $425.64 | $51.41 |
52-Week Low | $179.42 | $37.54 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SGOL, a US-listed gold-focused asset, trades at $39.63, down 0.13% amid a bearish technical signal. Key support lies at $39, with resistance at $40. The broader gold market faces pressure from rising Treasury yields and a firm dollar, as recent news highlights mixed sentiment with some analysts projecting declines while others see long-term potential. Financial ratios are unavailable in the provided data.
The outlook for SGOL is cautious near-term due to macroeconomic headwinds like interest rate uncertainty, but potential for recovery exists if inflation or geopolitical tensions boost gold's appeal. Risks include yield volatility and Fed policy shifts, while institutional interest may provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
